Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Longeveron Inc. Market Cap
The Longeveron Inc. (LGVN) share price is expected to increase by 352.81% over the next year. This is based on calculating the average 12-month share price estimate provided by 3 stock analysts who have covered LGVN. Price targets range from $6 at the low end to $10 at the high end. The current analyst consensus for LGVN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
LGVN is a stock in Healthcare which has been forecasted to be worth $8.875 as an average. On the higher end, the forecast price is $10 USD by Raghuram Selvaraju from HC Wainwright & Co. and on the lower end LGVN is forecasted to be $6 by Raghuram Selvaraju from HC Wainwright & Co..
These are the latest 20 analyst ratings of LGVN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Boobalan Pachaiyappan Roth MKM | Buy | $10 | Initiates | Dec 5, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Nov 25, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Nov 4, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Sep 4, 2024 |
| Michael Okunewitch Maxim Group | Buy | $6 | Maintains | Aug 27, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 15, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 31, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Maintains | Jul 29, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $12 | Reiterates | May 17, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $12 | Maintains | Apr 29, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Initiates | Dec 4, 2023 |
| Fozia Ahmed EF Hutton | Buy | $12.5 | Assumes | Jun 1, 2023 |
| Constantine Davides EF Hutton | Buy | $12.5 | Reiterates | May 16, 2023 |
| Constantine Davides EF Hutton | Buy | $12.5 | Reiterates | May 9, 2023 |
| Constantine Davides EF Hutton | Buy | $12.5 | Reiterates | Mar 27, 2023 |
| Constantine Davides EF Hutton | Buy | $12.5 | Maintains | Jan 10, 2023 |
| Michael Okunewitch Maxim Group | Buy | $14 | Initiates | Mar 24, 2022 |
EF Hutton | Buy | Initiates | Jan 5, 2022 |
When did it IPO
2021
Staff Count
23
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Mohamed Wa'el Ahmed Hashad M.B.A.
Market Cap
$30.7M
In 2023, LGVN generated $709,000 in revenue, which was a decrease of -41.98% from the previous year. This can be seen as a signal that LGVN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Longeveron Inc. (NASDAQ: LGVN) will present at the Emerging Growth Virtual Conference on December 5, 2024, from 12:00 to 12:30 p.m. ET, focusing on its cellular therapies.
Why It Matters - Longeveron’s participation in the Emerging Growth Virtual Conference highlights its visibility and potential to attract investor interest, signaling growth opportunities in regenerative medicine.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Longeveron, Inc. (NASDAQ: LGVN) will hold its Q3 2024 Earnings Conference Call on November 12, 2024, at 4:30 PM ET, featuring key company executives.
Why It Matters - The earnings call provides insights into Longeveron's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Longeveron has appointed Devin Blass as CTO and SVP of CMC, effective December 2, to enhance capabilities in preparation for a potential BLA filing.
Why It Matters - Longeveron's appointment of a CTO enhances its leadership and R&D capabilities, signaling progress towards a Biologics License Application (BLA), which can impact stock performance and investor sentiment.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Longveron will release its Q3 2024 financial results and business update on November 12th, after U.S. market close.
Why It Matters - Longveron's Q3 2024 financial results and business update may impact its stock price, revealing performance trends and future prospects that influence investor sentiment and decisions.
Sun, 27 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Longeveron Inc. reported 100% survival in patients treated with Lomecel-B TM post-stage 2 Glenn surgery in the ELPIS I study, outperforming prior trial data. ELPIS II is ongoing.
Why It Matters - Positive long-term survival data for Lomecel-B TM in HLHS patients enhances Longeveron Inc.'s credibility and potential market value, indicating promising growth prospects and reduced heart transplant needs.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Longeveron Inc. (NASDAQ: LGVN) presented findings on Lomecel-B™ at the CTAD24 conference, highlighting its potential to improve outcomes in mild Alzheimer's disease through MMP14 inhibition.
Why It Matters - Longeveron Inc.'s Lomecel-B™ shows promise in treating mild Alzheimer's, potentially boosting its stock value and attracting investor interest in innovative biotech solutions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
